Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration said on Friday.
Shares of obesity-drug maker Novo Nordisk rose Friday after the Food and Drug Administration declared that the company’s popular medications Ozempic and Wegovy were no longer in shortage. A shortage o ...
Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...
The big pharma sector is one that’s generally fallen out of favor for many investors over the past few decades, as large ...
David Ricks said drugs like Mounjaro and Zepbound are priced to reflect the costs involved, patent expiry, and the enormous ...
Pharmaceutical company Eli Lilly (LLY) has been raking it in lately thanks to its two flagship products: Mounjaro and Zepbound. These two have ...
Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...
Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...
Eli Lilly’s profit doubled in the fourth quarter ... Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of 2024 while ...
Eli Lilly’s momentum stems from blockbuster GLP-1 therapies (Mounjaro, Zepbound), fuelling revenue growth, long-term margin expansion, and an ethos driving America’s health focus across ...
(Reuters) -Eli Lilly on Thursday suggested that demand for its popular ... believed there was huge demand for its weight-loss drug Zepbound and diabetes treatment Mounjaro from hundreds of millions of ...
Eli Lilly’s new products (products launched since 2022 like Ebglyss, Jaypirca, Mounjaro, Kisunla, Omvoh and Zepbound) contributed $5.64 billion to revenues, led by Mounjaro and Zepbound.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results